Short-term effects of allulose consumption on glucose homeostasis, metabolic parameters, incretin levels, and inflammatory markers in patients with type 2 diabetes: a double-blind, randomized, controlled crossover clinical trial
- 11 July 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Nutrition
- Vol. 62 (7) , 2939-2948
Abstract
Purpose Allulose is a rare monosaccharide with almost zero calories. There is no study of short-term allulose consumption in patients with type 2 diabetes (T2D). Thus, we aimed to study the effect of allulose consumption for 12 weeks on glucose homeostasis, lipid profile, body composition, incretin levels, and inflammatory markers in patients with T2D. Methods A double-blind, randomized, controlled crossover study was conducted on sixteen patients with T2D. Patients were randomly assigned to allulose 7 g twice daily or aspartame 0.03 g twice daily for 12 weeks. After a 2-week washout, patients were crossed over to the other sweetener for an additional 12 weeks. Oral glucose tolerance tests, laboratory measurements, and dual-energy X-ray absorptiometry were conducted before and after each phase. Results This study revealed that short-term allulose consumption exerted no significant effect on glucose homeostasis, incretin levels, or body composition but significantly increased MCP-1 levels (259 ± 101 pg/ml at baseline vs. 297 ± 108 pg/mL after 12 weeks of allulose, p = 0.002). High-density lipoprotein cholesterol (HDL-C) significantly decreased from 51 ± 13 mg/dl at baseline to 41 ± 12 mg/dL after 12 weeks of allulose, p < 0.001. Conclusion Twelve weeks of allulose consumption had a neutral effect on glucose homeostasis, body composition, and incretin levels. Additionally, it decreased HDL-C levels and increased MCP-1 levels. Trial registration This trial was retrospectively registered on the Thai Clinical Trials Registry (TCTR20220516006) on December 5, 2022.Keywords
Funding Information
- the Innovation and Technology Assistance Program (ITAP) of the National Science and Technology Development Agency
- the Rajburi Sugar Co., Ltd.
This publication has 31 references indexed in Scilit:
- Rare sugar D-psicose prevents progression and development of diabetes in T2DM model Otsuka Long-Evans Tokushima Fatty ratsDrug Design, Development and Therapy, 2015
- The Epidemiology of Obesity: A Big PicturePharmacoEconomics, 2014
- Rare sugar d-psicose improves insulin sensitivity and glucose tolerance in type 2 diabetes Otsuka Long-Evans Tokushima Fatty (OLETF) ratsBiochemical and Biophysical Research Communications, 2011
- Study on the Postprandial Blood Glucose Suppression Effect ofD-Psicose in Borderline Diabetes and the Safety of Long-Term Ingestion by Normal Human SubjectsBioscience, Biotechnology, and Biochemistry, 2010
- Failure of d-psicose absorbed in the small intestine to metabolize into energy and its low large intestinal fermentability in humansMetabolism, 2010
- Development of obesity in the Otsuka Long-Evans Tokushima Fatty ratAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- HDL-Associated Lysosphingolipids Inhibit NAD(P)H Oxidase-Dependent Monocyte Chemoattractant Protein-1 ProductionArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- d-Psicose inhibits the expression of MCP-1 induced by high-glucose stimulation in HUVECsLife Sciences, 2007
- Relationship between Expression Levels and Atherogenesis in Scavenger Receptor Class B, Type I TransgenicsJournal of Biological Chemistry, 2000
- Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levelsNature, 1997